Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.49) by 28.57 percent. This is a 28.57 percent increase over losses of $(0.49) per share from the same period last year.